Core Insights - Conestoga Capital Advisors reported a -5.75% return for its Mid Cap Strategy in Q4 2025, underperforming the Russell Midcap Growth Index which returned -3.70% [1] - The full-year return for the Mid Cap Composite was -4.73%, significantly trailing the benchmark return of 8.66% [1] Company Overview: West Pharmaceutical Services, Inc. (NYSE:WST) - West Pharmaceutical Services, Inc. specializes in designing, manufacturing, and selling containment and delivery systems for injectable drugs and healthcare products [2][3] - As of February 19, 2026, the stock price was $243.83, with a one-month return of 3.03% and a 52-week gain of 15.61% [2] - The company has a market capitalization of $17.566 billion [2] Performance Drivers - The strong performance of West Pharmaceutical was attributed to momentum in its High-Value Products segment, particularly in GLP-1 obesity and diabetes therapies [3] - Management noted that previous destocking headwinds have moderated, allowing for a return to sustainable volume growth [3] - The company is positioned to benefit from long-term trends towards biologic and injectable medicines [3] Hedge Fund Interest - West Pharmaceutical is held by 49 hedge fund portfolios at the end of Q3 2025, an increase from 46 in the previous quarter [4] - Despite its potential, the company is not among the 30 most popular stocks among hedge funds, with some analysts suggesting that certain AI stocks may offer greater upside potential [4]

Surpassed $1 billion in annual sales in 2025, driven by record fourth-quarter pump shipments and double-digit growth in both U.S. and international markets. Management is fundamentally reshaping the business model by transitioning to a 'pay-as-you-go' (PayGo) reimbursement structure in the pharmacy channel to reduce patient out-of-pocket barriers. The shift to pharmacy is expected to double the lifetime revenue per patient while streamlining the prescription process for healthcare providers and improv ...

Company Overview - Senseonics has launched the full U.S. availability of its Eversense 365 Continuous Glucose Monitoring (CGM) system, integrated with Sequel Med Tech's twiist Automated Insulin Delivery (AID) system for type 1 diabetes patients [1][7] - The Eversense 365 CGM system offers a wear time of up to 365 days, significantly longer than the maximum of 15 days for other approved CGM devices from competitors like DexCom and Abbott [2][7] Financial Performance - Senseonics reported total revenues of $21 million, which is considerably lower than competitors DexCom and Abbott, who recorded $5.6 billion and $3.4 billion in sales related to CGM devices, respectively, in the first nine months of 2025 [4] - The company expects total revenues for 2026 to be in the range of $58-$62 million, representing an increase of 65% to 76% over 2025 revenue [12] Market Dynamics - The total CGM devices market size was valued at $13.66 billion in 2024 and is projected to grow at a CAGR of 15.4%, reaching $49.87 billion by 2033, driven by the rising prevalence of diabetes and technological advancements [10] - The integration of Eversense 365 with the twiist AID system is expected to enhance customer adoption and drive sales growth in 2026 [4][8] Recent Developments - Senseonics received CE Mark approval for the Eversense 365 CGM system and plans to launch it in Germany, Italy, Spain, and Sweden in the coming months [11] - The company reported a 71% year-over-year increase in total revenues for the fourth quarter of 2025, with new patients in the U.S. increasing by 103% from the previous year [12]

Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTech innovation companyHUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, today announced that effective with the open of the market on February 24, 2026, the Company will complete a 1-for-12 rever ...

REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “ ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medtronic will lay off 81 employees from a facility in Northridge, California, that works on diabetes devices, according to a state Worker Adjustment and Retraining Notification notice, filed Feb. 5. The cuts will go into effect on April 7. Medtronic does not plan to close the entire facility, but to restructure certain operations, according to a WARN letter. The af ...

Core Viewpoint - Johnson & Johnson is preparing to potentially sell its orthopedics unit, DePuy Synthes, with a deal that could exceed $20 billion, targeting private equity firms as likely buyers [1][2]. Group 1: Company Strategy - J&J announced plans to separate its orthopedics unit into a standalone company within 18 to 24 months, marking its second major spinoff in two years to focus on higher-growth healthcare segments [2]. - The company is currently assembling documents and financials for DePuy Synthes in anticipation of meetings with potential buyers in the coming weeks [2]. Group 2: Financial Performance - J&J's orthopedics unit generated $9.3 billion in sales in 2025, producing products such as hip, knee, and shoulder implants, as well as surgical instruments [3]. Group 3: Legal Issues - The company has faced thousands of lawsuits related to hip replacement devices from the orthopedics unit, with 128 claims remaining unresolved out of nearly 10,600 in nationwide litigation concerning alleged design defects in DePuy's ASR hip replacement system [3][4]. Group 4: Separation Process - The CFO of J&J indicated that the company is exploring multiple paths for the separation, primarily focusing on a tax-free spinoff, while remaining open to other options [4]. - The separation process is already underway, with no significant updates expected until mid-2026 [4].

Internationally, Q4 sales grew 17% year over year to $80 million on 11,000 pump shipments, aided by growth in both pump and supply shipments. Vosseller noted favorable foreign exchange, offset by $4 million tied to the company’s transition to direct operations that primarily affected pump sales. For 2025, total distributor destocking and inventory buyback impact was about $7 million, below the company’s earlier estimate of $10 million due to a partial timing shift into the first quarter of 2026.In the fourt ...

On profitability, gross margin in the fourth quarter was 70.9% (up 90 basis points year over year), while full-year gross margin was 70.6% (up 170 basis points). Wilson said the improvement reflected operational efficiencies in manufacturing, automation, and workflow optimization, along with scale benefits, partially offset by product mix.Wilson noted that “new store” growth—accounts open less than 12 months—represented approximately 68% of year-over-year volume growth. U.S. home enrollment for Zio Services ...

Core Insights - ICU Medical reported fourth-quarter 2025 revenue of $536 million, achieving 2% organic growth and 5% organic growth for the full year, with record performance in consumables and infusion systems [4][7] - The company delivered adjusted EBITDA of $98 million and adjusted earnings per share of $1.91, with gross margins remaining above 40% [3][7] - The 2026 outlook anticipates low- to mid-single-digit organic growth, adjusted EBITDA of $400–430 million, and adjusted EPS of $7.75–8.45, with a focus on improving free cash flow to reduce debt [5][15] Financial Performance - Adjusted SG&A expenses were reported at $113 million, and adjusted R&D expenses were $21 million, totaling adjusted operating expenses of $134 million, which is 25% of revenue [1] - The adjusted gross margin for the quarter was 40.5%, consistent with prior guidance of 40% to 41%, impacted by $11 million in tariff expenses [2][7] - Adjusted EBITDA declined 7% year-over-year from $106 million, primarily due to the deconsolidation of IV Solutions and tariff impacts, representing a $25 million EBITDA headwind [7] Business Segments - Consumables revenue grew 6% reported and 5% organic in Q4, with full-year growth of 7% reported and 6% organic, driven by strong demand in infusion consumables and oncology [8] - Infusion systems revenue increased 3% reported and 1% organic in Q4, with expectations of mid-single-digit organic growth in the near term [16] - Vital Care experienced a 6% organic decline and a 35% reported decline due to the IV Solutions deconsolidation, with management focusing on discontinuing loss-making SKUs [16] Regulatory and Integration Updates - The company closed a broad FDA warning letter related to Smiths Medical and completed major manufacturing and ERP integrations, which are expected to unlock synergies [6][11] - ICU Medical is pursuing 510(k) clearances for key products, including the Medfusion 5000 syringe pump and LifeShield software, as part of its strategy to enhance product offerings [10] 2026 Guidance and Strategic Focus - The company projects full-year adjusted gross margin of around 41%, with improvements expected throughout the year, despite manufacturing inflation and tariff expenses [14] - Free cash flow is expected to improve in 2026, with a focus on debt reduction and a long-term leverage target of 2x by early 2027 [18] - Management indicated that any strategic moves would need to avoid value destruction, particularly in the Critical Care segment, which is seen as less synergistic [19]